"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...
Funds to support ongoing Phase 1 trial of MNA-001 and validation of translational biomarkers for TREM2 function in Alzheimer's Work will inform Phase 2 trials assessing the potential of MNA-001 to ...
Zacks Investment Research on MSN
VKTX completes enrollment in phase I maintenance study of obesity drug
Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of ...
MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...
1d
GLP-1 receptor agonists tied to reduced acute asthma exacerbations in teens with overweight, obesity
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a lower risk for acute asthma exacerbations in ...
Among adolescents with asthma and overweight or obesity, the relative risk for acute asthma exacerbations was significantly reduced with GLP-1 receptor agonist use vs. nonpharmacological weight ...
Lysoway Therapeutics, Inc., a biotechnology company advancing structure-guided small-molecule modulators of lysosomal ion ...
Rachael Link is a registered dietitian and health writer based in San Francisco. She completed her undergraduate degree at the University of Central Missouri and holds a master’s degree from New York ...
Lysoway Therapeutics, Inc., a biotechnology company advancing structure-guided small-molecule modulators of lysosomal ion channels to treat age-related neurodegeneration, today announced that its lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback